Cargill Inc.

Sasya Inc.

Kevin Roberg-Perez

Aristos Aristidou

Kari Koivuranta

Brian Jeffrey Rush

Pirkko Suominen

Catherine Asleson Dundon

Thomas W McMullin

Benjamin Matthew Hause

Goutham Vemuri

Elizabeth A Cameron

Christopher D Snow

Laura Ruohonen

Marja Ilmen

Merja Pentilla

Pirrko Suominen

Thomas William McMULLIN

Christopher Lindsay

The biological production of beta-hydroxyisovalerate (βHIV) using at least one non-natural enzyme. The non-natural enzyme for the biologically-derived βHIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural enzyme having one or more modifications of substrate-specificity positions. The non-natural enzyme can be expressed in a microorganism, such as a yeast or bacteria, wherein the microorganism comprises an active βHIV metabolic pathway for the production of βHIV. Alternatively, the non-natural enzyme can be a βHIV synthase used to produce βHIV in a cell-free environment. The biological derivation of βHIV eliminates toxic by-products and impurities that result from the chemical production of βHIV, such that βHIV produced by a non-natural enzyme prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.

Synthesis of beta-hydroxyisovalerate and methods of use

The biological production of beta-hydroxyisovalerate (βHIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived βHIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active βHIV metabolic pathway for the production of βHIV. The biological derivation of βHIV eliminates toxic by-products and impurities that result from the chemical production of βHIV, such that βHIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.

Yeast cells are genetically modified to disrupt a native metabolic pathway from dihydroxyacetone to glycerol. In certain aspects, the yeast cell is of the generaor. In other aspects, the yeast cell is capable of producing at least one organic acid, such as lactate. The yeast cells produce significantly less glycerol than the wild-type strains, and usually produce greater yields of desired fermentation products. Yeast cells of the invention often grow well when cultivated, despite their curtailed glycerol production.

Yeast cells having disrupted pathway from dihydroxyacetone phosphate to glycerol

Fermentation process using yeast cells having disrupted pathway from dihydroxyacetone phosphate to glycerol

Cells of the speciesand closely related yeast species are transformed with a vector to introduce an exogenous lactate dehydrogenase gene. The cells produce lactic acid efficiently and are resistant at low pH, high lactate titer conditions.

[object Object]

Growing community of inventors

Minneapolis, MN, United States of America

Kevin Roberg-Perez